Glucagon-like peptide 1 receptor agonists in the practice of an obstetrician-gynecologist

DOI

https://dx.doi.org/10.18565/aig.2025.313

Apolikhina I.A., Khadzhieva N.Kh., Alieva A.M.
1) Academician V.I. Kulakov National Medical Research Centre for Obstetrics, Gynecology and Perinatology, Ministry of Health of Russia, Moscow, Russia; 2) I.M. Sechenov First Moscow State Medical University, Ministry of Health of Russia (Sechenov University), Moscow, Russia; 3) Clinic on Pokrovka LLC, Moscow, Russia; 4) N.I. Pirogov Russian National Research Medical University, Ministry of Health of Russia, Moscow, Russia

Obesity is a serious public health problem characterized by multiple organ dysfunction, including reproductive disorders. Given the relationship between obesity, type 2 diabetes, cardiovascular and renal pathology, the American Heart Association introduced the term “cardiovascular-kidney-metabolic syndrome” in 2023, thus expanding the concept of metabolic syndrome. Therapeutic lifestyle modification is the main intervention, in addition to which glucagon-like peptide 1 receptor agonists (GLP-1RAs) have recently been used for weight loss. According to the results of clinical studies, GLP-1RAs improve metabolic parameters and fertility in patients with polycystic ovary syndrome (PCOS), obesity and in patients without PCOS. Research is currently conducted on the use of GLP-1RAs for women with endometrial hyperplasia, and therefore, GLP-1RAs are of interest to obstetricians and gynecologists. This article discusses the effects of GLP-1 and its agonists, the safety of GLP-1RAs in relation to pregnancy and also drug interactions.
Conclusion: The use of drugs that affect weight loss, glycemic profile, and metabolism of lipids involved in the normalization of the menstrual cycle and ovulation can prevent adverse reproductive and metabolic disorders leading to an increased incidence of major adverse cardiovascular events (MACE) in patients with PCOS.

Authors’ contributions: Apolikhina I.A. – editing the article material; Khadzhieva N.Kh., Alieva A.M. – collecting publications, processing and analysis of materials, writing the text, translation of articles.
Conflicts of interest: The authors declare that there are no conflicts of interest.
Funding: The study was conducted without sponsorship.
For citation: Apolikhina I.A., Khadzhieva N.Kh., Alieva A.M. Glucagon-like peptide 1
receptor agonists in the practice of an obstetrician-gynecologist.
Akusherstvo i Ginekologiya/Obstetrics and Gynecology. 2026; (4): 44-50 (in Russian)
https://dx.doi.org/10.18565/aig.2025.313

polycystic ovary syndrome

obesity

semaglutide

glucagon-like peptide 1 receptor agonists

obesity therapy

tirzepatide

incretins

Full text (in Russian)

World Health Organization. Obesity. Available at: https://www.who.int/westernpacific/health-topics/obesity#tab=tab_1
World Obesity Federation. World Obesity Atlas 2023. Available at: https://www.worldobesityday.org/assets/downloads/World_Obesity_Atlas_2023_Report.pdf
World Obesity Federation. World Obesity Atlas 2025. Available at: https://www.worldobesity.org/resources/resource-library/world-obesity-atlas-2025
Титова В.В., Ушанова Ф.О., Демидова Т.Ю. Медикаментозная терапия ожирения: современные подходы и перспективы. FOCUS Эндокринология. 2024; 5(4): 40-8. [Titova V.V., Ushanova F.O., Demidova T.Yu. Medical treatment of obesity: modern approaches and prospects. FOCUS Endocrinology. 2024; 5(4): 40-8 (in Russian)]. https://dx.doi.org/10.62751/2713-0177-2024-5-4-18
Fitch A.K., Bays H.E. Obesity definition, diagnosis, bias, standard operating procedures (SOPs), and telehealth: an Obesity Medicine Association (OMA) Clinical Practice Statement (CPS) 2022. Obes. Pillars. 2022; 1: 100004. https://dx.doi.org/10.1016/j.obpill.2021.100004
Аметов А.С., Туркина С.В. Дисфункция жировой ткани: в фокусе ожирение, сахарный диабет и сердечно-сосудистые заболевания, неалкогольная жировая болезнь печени. Эндокринология: новости, мнения, обучение. 2024; 13(4): 84-93. [Ametov A.S., Turkina S.V. Adipose tissue dysfunction: focus on obesity, diabetes and cardiovascular disease, nonalcoholic fatty liver disease. Endocrinology: News, Opinions, Training. 2024; 13(4): 84-93 (in Russian)]. https://dx.doi.org/10.33029/2304-9529-2024-13-4-84-93
Schon S.B., Cabre H.E., Redman L.M. The impact of obesity on reproductive health and metabolism in reproductive-age females. Fertil. Steril. 2024; 122(2): 194-203. https://dx.doi.org/10.1016/j.fertnstert.2024.04.036
Amiri M., Ramezani Tehrani F. Potential adverse effects of female and male obesity on fertility: a narrative review. Int. J. Endocrinol. Metab. 2020; 18(3): e101776. https://dx.doi.org/10.5812/ijem.101776
Министерство здравоохранения Российской Федерации. Клинические рекомендации. Ожирение. 2024. Доступно по: https://cr.minzdrav.gov.ru/preview-cr/28_3 [Ministry of Health of the Russian Federation. Clinical guidelines. Obesity. 2024. Available at: https://cr.minzdrav.gov.ru/preview-cr/28_3 (in Russian)].
Busetto L., Dicker D., Frühbeck G., Halford J.C.G., Sbraccia P., Yumuk V. et al. A new framework for the diagnosis, staging and management of obesity in adults. Nat. Med. 2024; 30(9): 2395-9. https://dx.doi.org/10.1038/s41591-024-03095-3
Hassapidou M., Vlassopoulos A., Kalliostra M., Govers E., Mulrooney H., Ells L. et al. European association for the study of obesity position statement on medical nutrition therapy for the management of overweight and obesity in adults developed in collaboration with the European Federation of the Associations of dietitians. Obes. Facts. 2023; 16(1): 11-28. https://dx.doi.org/10.1159/000528083
Filippi-Arriaga F., Agarwal N., Rodrigues-Martins D., Monteiro M.P., Huvinen E., Suliman S.G.I. et al. EASO position statement: women with obesity across the reproductive life – fertility, preconception, pregnancy, postpartum, and breastfeeding. Obes. Facts. 2025; 18(6): 625-39. https://dx.doi.org/10.1159/000546449
Куркин Д.В., Бакулин Д.А., Морковин Е.И., Петров В.И., Стрыгин А.В., Корянова К.Н., Горбунова Ю.В., Колосов Ю.А., Иванова О.В., Павлова Е.В., Джавахян М.А., Заборовский А.В., Сапарова В.Б., Макаренко И.Е., Драй Р.И., Чумаченко А.Н. Физиология и фармакология рецептора глюкагоноподобного пептида-1. Фармация и фармакология. 2023; 11(4): 347-80. [Kurkin D.V., Bakulin D.A., Morkovin E.I., Petrov V.I., Strygin A.V., Koryanova K.N., Gorbunova Yu.V., Kolosov Yu.A., Ivanova O.V., Pavlova E.V., Dzhavakhyan M.A., Zaborovsky A.V., Saparova V.B., Makarenko I.E., Drai R.I., Chumachenko A.N. Physiology and pharmacology of glucagon-like peptide-1 receptor. Pharmacy & Pharmacology. 2023; 11(4): 347-80 (in Russian)]. https://dx.doi.org/10.19163/2307-9266-2023-11-4-347-380
Müller T.D., Adriaenssens A., Ahrén B., Blüher M., Birkenfeld A.L., Campbell J.E. et al. Glucose-dependent insulinotropic polypeptide (GIP). Mol. Metab. 2025; 95: 102118. https://dx.doi.org/10.1016/j.molmet.2025.102118
Tanday N., Flatt P.R., Irwin N. Metabolic responses and benefits of glucagon-like peptide-1 (GLP-1) receptor ligands. Br. J. Pharmacol. 2022; 179(4): 526-41. https://dx.doi.org/10.1111/bph.15485
Drucker D.J., Holst J.J. The expanding incretin universe: from basic biology to clinical translation. Diabetologia. 2023; 66(10): 1765-79. https://dx.doi.org/10.1007/s00125-023-05906-7
Ussher J.R., Drucker D.J. Glucagon-like peptide 1 receptor agonists: cardiovascular benefits and mechanisms of action. Nat. Rev. Cardiol. 2023; 20(7): 463-74. https://dx.doi.org/10.1038/s41569-023-00849-3
Цыганкова О.В., Веретюк В.В., Аметов А.С. Инкретины сегодня: множественные эффекты и терапевтический потенциал. Сахарный диабет. 2019; 22(1): 70-8. [Tsygankova O.V., Veretyuk V.V., Ametov A.S. Incretins today: multiple effects and therapeutic potential. Diabetes Mellitus. 2019; 22(1): 70-8 (in Russian)]. https://dx.doi.org/10.14341/DM9841
Jensterle M., Janez A., Fliers E., DeVries J.H., Vrtacnik-Bokal E., Siegelaar S.E. The role of glucagon-like peptide-1 in reproduction: from physiology to therapeutic perspective. Hum. Reprod. Update. 2019; 25(4): 504-17. https://dx.doi.org/10.1093/humupd/dmz019
Farkas I., Vastagh C., Farkas E., Bálint F., Skrapits K., Hrabovszky E. et al. Glucagon-like peptide-1 excites firing and increases GABAergic miniature postsynaptic currents (mPSCs) in gonadotropin-releasing hormone (GnRH) neurons of the male mice via activation of nitric oxide (NO) and suppression of endocannabinoid signaling pathways. Front. Cell. Neurosci. 2016; 10: 214. https://dx.doi.org/10.3389/fncel.2016.00214
Outeiriño-Iglesias V., Romaní-Pérez M., González-Matías L.C., Vigo E., Mallo F. GLP-1 increases preovulatory LH source and the number of mature follicles, as well as synchronizing the onset of puberty in female rats. Endocrinology 2015; 156(11): 4226-37. https://dx.doi.org/10.1210/en.2014-1978
Heppner K.M., Baquero A.F., Bennett C.M., Lindsley S.R., Kirigiti M.A., Bennett B. et al. GLP-1R signaling directly activates arcuate nucleus kisspeptin action in brain slices but does not rescue luteinizing hormone inhibition in ovariectomized mice during negative energy balance. eNeuro. 2017; 4(1): ENEURO.0198-16.2016. https://dx.doi.org/10.1523/ENEURO.0198-16.2016
MacLusky N.J., Cook S., Scrocchi L., Shin J., Kim J., Vaccarino F. et al. Neuroendocrine function and response to stress in mice with complete disruption of glucagon-like peptide-1 receptor signaling. Endocrinology. 2000; 141(2): 752-62. https://dx.doi.org/10.1210/endo.141.2.7326
Nishiyama Y., Hasegawa T., Fujita S., Iwata N., Nagao S., Hosoya T. et al. Incretins modulate progesterone biosynthesis by regulating bone morphogenetic protein activity in rat granulosa cells. J. Steroid. Biochem. Mol. Biol. 2018; 178: 82-8. https://dx.doi.org/10.1016/j.jsbmb.2017.11.004
Bou Nemer L., Shi H., Carr B.R., Word R.A., Bukulmez O. Effect of body weight on metabolic hormones and fatty acid metabolism in follicular fluid of women undergoing in vitro fertilization: a pilot study. Reprod. Sci. 2019; 26(3): 404-11. https://dx.doi.org/10.1177/1933719118776787
Sola-Leyva A., Pathare A.D.S., Apostolov A., Aleksejeva E., Kask K., Tammiste T. et al. The hidden impact of GLP-1 receptor agonists on endometrial receptivity and implantation. Acta Obstet. Gynecol. Scand. 2025; 104(2): 258-66. https://dx.doi.org/10.1111/aogs.15010
Zhang Y., Xu F., Liang H., Cai M., Wen X., Li X. et al. Exenatide inhibits the growth of endometrial cancer Ishikawa xenografts in nude mice. Oncol. Rep. 2016; 35(3): 1340-8. https://dx.doi.org/10.3892/or.2015.4476
Kanda R., Hiraike H., Wada-Hiraike O., Ichinose T., Nagasaka K., Sasajima Y. et al. Expression of the glucagon-like peptide-1 receptor and its role in regulating autophagy in endometrial cancer. BMC Cancer. 2018; 18(1): 657. https://dx.doi.org/10.1186/s12885-018-4570-8
Artunc-Ulkumen B., Pala H.G., Pala E.E., Yavasoglu A., Yigitturk G., Erbas O. Exenatide improves ovarian and endometrial injury and preserves ovarian reserve in streptozocin induced diabetic rats. Gynecol. Endocrinol. 2015; 31(3): 196-201. https://dx.doi.org/10.3109/09513590.2014.975686
Hagemann A.R., Hagemann I.S., Mutch D.G., Devor E.J., Malmrose P.K., Zhang Y. et al. Enhancing progestin therapy with a glucagon-like peptide 1 agonist for the conservative management of endometrial cancer. Cancers (Basel). 2025; 17(4): 598. https://dx.doi.org/10.3390/cancers17040598
Tao X., Zhang X., Ge S.Q., Zhang E.H., Zhang B. Expression of SIRT1 in the ovaries of rats with polycystic ovary syndrome before and after therapeutic intervention with exenatide. Int. J. Clin. Exp. Pathol. 2015; 8(7): 8276-83.
Zhang W., Zhang J. Semaglutide pretreatment induces cardiac autophagy to reduce myocardial injury in septic mice. Discov. Med. 2023; 35(178): 853-60. https://dx.doi.org/10.24976/Discov.Med.202335178.80
Sills E.S., Harrity C., Chu H.I., Wang J.W., Yang F., Wood S.H. Semaglutide and human reproduction: caution at the intersection of energy balance, ovarian function, and follicular development. Reprod. Biol. Endocrinol. 2025; 23(1): 116. https://dx.doi.org/10.1186/s12958-025-01435-7
Saber S.M., Abd El-Rahman H.A. Liraglutide treatment effects on rat ovarian and uterine tissues. Reprod. Biol. 2019; 19(3): 237-44. https://dx.doi.org/10.1016/j.repbio.2019.07.003
Krasnyi A.M., Sadekova A.A., Smolnova T.Y., Chursin V.V., Buralkina N.A., Chuprynin V.D. et al. The levels of ghrelin, glucagon, visfatin and Glp-1 are decreased in the peritoneal fluid of women with endometriosis along with the increased expression of the CD10 protease by the macrophages. Int. J. Mol. Sci. 2022; 23(18): 10361. https://dx.doi.org/10.3390/ijms231810361
Ndumele Ch.E., Neeland I.J., Tuttle K.R., Chow S.L., Mathew R.O., Khan S.S. et al. A synopsis of the evidence for the science and clinical management of сardiovascular-kidney-metabolic (CKM) syndrome: a scientific statement from the American heart association. Circulation. 2023; 148(20): 1636-64. https://dx.doi.org/10.1161/CIR.0000000000001186
Guldan M., Unlu S., Abdel-Rahman S.M., Ozbek L., Gaipov A., Covic A. et al. Understanding the role of sex hormones in cardiovascular kidney metabolic syndrome: toward personalized therapeutic approaches. J. Clin. Med. 2024; 13(15): 4354. https://dx.doi.org/10.3390/jcm13154354
Демидова Т.Ю., Никитин И.Г., Кисляк О.А., Стародубова А.В. Роль агонистов рецепторов ГПП-1 в управлении кардиометаболическим здоровьем. FOCUS Эндокринология. 2024; 5(4): 76-87. [Demidova T.Yu., Nikitin I.G., Kislyak O.A., Starodubova A.V. The role of glucagon-like peptide-1 receptor agonists in cardiometabolic health management. FOCUS Endocrinology. 2024; 5(4): 76-87 (in Russian)]. https://dx.doi.org/10.62751/2713-0177-2024-5-4-22
Thethi T.K., Pratley R., Meier J.J. Safety and cardiovascular outcomes of once-daily oral semaglutide in patients with type 2 diabetes: the PIONEER programme. Diabetes Obes. Metab. 2020; 22(8): 1263-77. https://dx.doi.org/10.1111/dom.14054
Davies M., Faerch L., Jeppesen O.K., Pakseresht A., Pedersen S.D., Perreault L. et al. Semaglutide 2·4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial. Lancet. 2021; 397(10278): 971-84. https://dx.doi.org/10.1016/S0140-6736(21)00213-0
MacIsaac R.J. Semaglutide: a key medication for managing cardiovascular-kidney-metabolic syndrome. Future Cardiol. 2025; 21(9): 663-83. https://dx.doi.org/10.1080/14796678.2025.2511412
McGowan B., Ciudin A., Baker J.L., Busetto L., Dicker D., Frühbeck G. et al. Framework for the pharmacological treatment of obesity and its complications from the European association for the study of obesity (EASO). Nat. Med. 2025; 31(10): 3229-32. https://dx.doi.org/10.1038/s41591-025-03765-w
Aronne L.J., Horn D.B., le Roux C.W., Ho W., Falcon B.L., Gomez Valderas E. et al. Tirzepatide as compared with semaglutide for the treatment of obesity. N. Engl. J. Med. 2025; 393(1): 26-36. https://dx.doi.org/10.1056/NEJMoa2416394
Bednarz K., Kowalczyk K., Cwynar M., Czapla D., Czarkowski W., Kmita D. et al. The role of GLP-1 receptor agonists in insulin resistance with concomitant obesity treatment in polycystic ovary syndrome. Int. J. Mol. Sci. 2022; 23(8): 4334. https://dx.doi.org/10.3390/ijms23084334
Monney M., Mavromati M., Leboulleux S., Gariani K. Endocrine and metabolic effects of GLP-1 receptor agonists on women with PCOS, a narrative review. Endocr. Connect. 2025; 14(5): e240529. https://dx.doi.org/10.1530/EC-24-0529
Carmina E., Longo R.A. Semaglutide treatment of excessive body weight in obese PCOS patients unresponsive to lifestyle programs. J. Clin. Med. 2023; 12(18): 5921. https://dx.doi.org/10.3390/jcm12185921
Шабатукова Е.В., Щербань Д.А., Кудратова Е.А., Скворцова А.А., Жукова О.В. Современная фармакотерапия синдрома поликистозных яичников. Акушерство и гинекология. 2025; 7: 153-60. [Shabatukova E.V., Shcherban D.A., Kudratova E.A., Skvortsova A.A., Zhukova O.V. Modern pharmacotherapy of polycystic ovary syndrome Obstetrics and Gynecology. 2025; (7): 153-60 (in Russian)]. https://dx.doi.org/10.18565/aig.2025.83
Министерство здравоохранения Российской Федерации. Клинические рекомендации. Синдром поликистозных яичников. 2025. [Ministry of Health of the Russian Federation. Clinical guidelines. Polycystic ovary syndrome. 2025 (in Russian)].
Duah J., Seifer D.B. Medical therapy to treat obesity and optimize fertility in women of reproductive age: a narrative review. Reprod. Biol. Endocrinol. 2025; 23(1): 2. https://dx.doi.org/10.1186/s12958-024-01339-y
Howard M.D., Allen S.E. The use of GLP-1: receptor agonist medications for benign gynecology. Curr. Opin. Obstet. Gynecol. 2025; 37(4): 279-84. https://dx.doi.org/10.1097/GCO.0000000000001028
Varughese M.S., O'Mahony F., Varadhan L. GLP-1 receptor agonist therapy and pregnancy: Evolving and emerging evidence. Clin. Med. (Lond). 2025; 25(2): 100298. https://dx.doi.org/10.1016/j.clinme.2025.100298
Muller D.R.P., Stenvers D.J., Malekzadeh A., Holleman F., Painter R.C., Siegelaar S.E. Effects of GLP-1 agonists and SGLT2 inhibitors during pregnancy and lactation on offspring outcomes: a systematic review of the evidence. Front. Endocrinol. (Lausanne). 2023; 14: 1215356. https://dx.doi.org/10.3389/fendo.2023.1215356
Minis E., Stanford F.C., Mahalingaiah S. Glucagon-like peptide-1 receptor agonists and safety in the preconception period. Curr. Opin. Endocrinol. Diabetes Obes. 2023; 30(6): 273-9. https://dx.doi.org/10.1097/MED.0000000000000835
Dao K., Shechtman S., Weber-Schoendorfer C., Diav-Citrin O., Murad R.H., Berlin M. et al. Use of GLP1 receptor agonists in early pregnancy and reproductive safety: a multicentre, observational, prospective cohort study based on the databases of six Teratology information services. BMJ Open. 2024; 14(4): e083550. https://dx.doi.org/10.1136/bmjopen-2023-083550
Инструкция по медицинскому применению препарата СЕМАВИК®. Доступно по: https://semavic.ru/manual/?ysclid=mmpxmmoism135827637 [Instructions for medical use of SEMAVIC®. Available at: https://semavic.ru/manual/?ysclid=mmpxmmoism135827637 (in Russian)].
Аметов А.С., Шохин И.Е., Рогожина Е.А., Бодрова Т.Г., Невретдинова М.Е., Белый П.А., Заславская К.Я., Щербакова В.С., Куркин Д.В., Корянова К.Н., Мищенко Е.С., Кесова Э.Ю., Козлов Е.Д., Самошкина Е.С., Андреев Д.Н., Казаишвили Ю.Г., Носков С.М., Балыкова Л.А. Сравнительный анализ физико-химических свойств, биоэквивалентности, безопасности и переносимости отечественного семаглутида. Фармация и фармакология. 2023; 11(4): 324-46. [Ametov A.S., Shokhin I.E., Rogozhina E.A., Bodrova T.G., Nevretdinova M.E., Bely P.A., Zaslavskaya K.Ya., Scherbakova V.S., Kurkin D.V., Koryanova K.N., Mishchenko E.S., Kesova E.Yu., Kozlov E.D., Samoshkina E.S., Andreev D.N., Kazaishvili Yu.G., Noskov S.M., Balykova L.A. Comparative analysis of physicochemical properties, bioequivalence, safety and tolerability of the first domestic semaglutide. Pharmacy & Pharmacology. 2023; 11(4): 324-46 (in Russian)]. https://dx.doi.org/10.19163/2307-9266-2023-11-4-324-346
Mounjaro (tirzepatide) [summary of product characteristics]. Eli Lilly Nederland BV. 2024. Available at: https://www.ema.europa.eu/en/documents/product-information/mounjaro-epar-product-information_en.pdf
Jordy A.B., Breitschaft A., Christiansen E., Granhall C., Hansen C.W.F., Houshmand-Oregaard A. et al. Oral semaglutide does not affect the bioavailability of the combined oral contraceptive ethinylestradiol/levonorgestrel. Diabetes. 2018; 67(S1): 1135-P. https://dx.doi.org/10.2337/db18-1135-P
Kapitza C., Nosek L., Jensen L., Hartvig H., Jensen C.B., Flint A. Semaglutide, a once-weekly human GLP-1 analog, does not reduce the bioavailability of the combined oral contraceptive, ethinylestradiol/levonorgestrel. J. Clin. Pharmacol. 2015; 55(5): 497-504. https://dx.doi.org/10.1002/jcph.443
British Menopause Society. Use of incretin-based therapies in women using hormone replacement therapy (HRT). 2025. Available at://thebms.org.uk/wp-content/uploads/2025/05/23-BMS-TfC-Use-of-incretin-based-therapies-APRIL2025-E.pdf
Joshi G.P., Abdelmalak B.B., Weigel W.A., Soriano S.G., Harbell M.W., Kuo C.I. et al.; American Society of Anesthesiologists (ASA) Task Force on Preoperative Fasting. American Society of Anesthesiologists consensus-based guidance on preoperative management of patients (adults and children) on glucagon-like peptide-1 (GLP-1) receptor agonists. 2023. Available at: https://www.asahq.org/about-asa/newsroom/news-releases/2023/06/american-society-of-anesthesiologists-consensus-based-guidance-on-preoperative

Received 29.10.2025

Accepted 12.02.2026

Inna A. Apolikhina, Dr. Med. Sci., Professor, Head of the Department of Aesthetic Gynecology and Rehabilitation, Academician V.I. Kulakov National Medical Research Center for Obstetrics, Gynecology and Perinatology, Ministry of Health of Russia, 117997, Russia, Moscow, Ac. Oparina str., 4; Professor at the Department of Obstetrics, Gynecology, Perinatology and Reproductology of the Institute of Vocational Education, I.M. Sechenov First Moscow State Medical University, Ministry of Health of Russia (Sechenov University), apolikhina@inbox.ru, https://orcid.org/0000-0002-4581-6295
Nyurzhanna Kh. Khadzhieva, PhD, obstetrician-gynecologist, Clinic on Pokrovka, 105062, Russia, Moscow, Pokrovka str., 31, bldg. 1, +7(926)535-56-90, nurzhanna@yandex.ru, https://orcid.org/0000-0002-5520-281X
Amina M. Alieva, PhD, Associate Professor at the Department of Hospital Therapy named after Academician G.I. Storozhakov of the Faculty of Medicine, N.I. Pirogov Russian National Research Medical University, Ministry of Health of Russia, 117513, Russia, Moscow, Ostrovityanova str., 1, amisha_alieva@mail.ru,
https://orcid.org/0000-0001-5416-8579
Corresponding author: Nyurzhanna Kh. Khadzhieva, nurzhanna@yandex.ru

Glucagon-like peptide 1 receptor agonists in the practice of an obstetrician-gynecologist

Apolikhina I.A., Khadzhieva N.Kh., Alieva A.M.

Keywords

References

About the Authors

Similar Articles